
MASTOCYTOSIS DIAGNOSIS, CLASSIFICATION, AND THERAPY

Peter Valent

HISTORY: MAST CELLS AND MASTERS

PAUL EHRLICH (1854-1915)




•	1869 - Nettelship	Rare Form of Urticaria
•	1878 - Sangster	Urticaria Pigmentosa UP
•	1879 - Ehrlich	Mast Cells (Mastzellen)
•	1887 - Unna	Mast Cells in UP
•	1949 - Ellis	Systemic Mastocytosis
•	1979 - Lennert	Kiel Classification
•	1991 - Metcalfe	Consensus Classification
•	1996 - Longley	c-kit D816V in SM
•	1998 - Escribano	CD2/CD25 on MC in SM
	1990-2000	Criteria Established
	2000	Working Conference
	2001	WHO Classification

MAST CELLS - BIOLOGY

- Hematopoietic Cells Leukocytes
- Directly derive from CD34⁺ Progenitor Cells
- Distributed in Connective Tissues
- Express Stem Cell Factor (SCF) Receptor = Kit
- Differentiate in the presence of SCF
- Are extremely long-lived Cells (contrasting basophils)
- Express Vasoactive Mediators (Histamine, others)
- Release Mediators on Activation (IgER, Kit,)

DIFFERENTIATION OF MAST CELLS



Cutaneous Mastocytosis (CM) vs Systemic Mastocytosis (SM) !



Mostly Children (monoclonal?)

- **Diagnosis:** Skin only
- Biopsy of Skin
- Serum Tryptase
- Usually no BM Biopsy

Cutaneous Mastocytosis



Mostly Adults (c-kit D816V) Diagnosis: MPD

- Biopsy of <u>BM</u> (and Skin)
- Apply SM Criteria
- Define SM Variant


Systemic Mastocytosis

WHO CLASSIFICATION



- Cutaneous Mastocytosis (CM)
- Indolent Systemic Mastocytosis (ISM)
- SM with an Associated Hematologic non Mast Cell Lineage Disease (SM-AHNMD)
- Aggressive Systemic Mastocytosis (ASM)
- Mast Cell Leukemia (MCL)
- Mast Cell Sarcoma (MCS)
- Extracutaneous Mastocytoma

Survival of Patients with Mast Cell Disorders defined by WHO Criteria



WHO Classification: Criteria for Systemic Mastocytosis (SM-Criteria)

Major Criteria


• Multifocal dense mast cell (MC) infiltrates (≥15 MC/infiltrate) in the bone marrow or in an other extracutaneous organ


Minor Criteria

- >25% spindle-shaped cells in MC-infiltates; or >25% of all MC are atypical MC (type I and/or type II) in bone marrow smears
- Expression of CD2 and/or CD25 on bone marrow MC
- Serum tryptase level >20 ng/ml (does not count in cases with an AHNMD)
- *c-kit* point mutation at codon 816 (mostly D816V) in bone marrow or in another extracutaneous organ

The diagnosis Systemic Mastocytosis is established if at least 1 major and 1 minor or 3 minor criteria are fulfilled

Analysis of Bone Marrow Sections: Tryptase-Immunohistochemistry






Systemic Mastocytosis

SM-AHNMD ? Myelomastocytic ?

Bone Marrow Smear: Atypical Mast Cells in Systemic Mastocytosis




Criteria for Atypical Mast Cells Type I in Bone Marrow Smears: A: Oval Nucleus, B: Cytoplasmic Extensions, C: Hypogranulated (2/3)



Bone Marrow Smear: Atypical Mast Cells Type II and Metachromatic Blasts




Atypical Mast Cells Type II = Promastocytes in Bone Marrow Smears




Sperr et al, Leuk Res 2001;25:529


Metachromatic Blasts in Bone Marrow Smears



Mast Cell Numbers in Bone Marrow Smears in Patients with SM: Clinical Significance

Survival of patients with varying percentages of pro-mastocytes (<u>of all</u> <u>mast cells</u>) in bone marrow smears





Sperr et al, Leuk Res 2001;25:529

WHO Classification: Criteria for Systemic Mastocytosis (SM-Criteria)



Major Criteria


• Multifocal dense mast cell (MC) infiltrates (≥15 MC/infiltrate) in the bone marrow or in an other extracutaneous organ

Minor Criteria


- >25% spindle-shaped cells in MC-infiltates; or >25% of all MC are atypical MC (type I and/or type II) in bone marrow smears
- Expression of CD2 and/or CD25 on bone marrow MC
- Serum tryptase level >20 ng/ml (does not count in cases with an AHNMD)
- *c-kit* point mutation at codon 816 (mostly D816V) in bone marrow or in another extracutaneous organ

The diagnosis Systemic Mastocytosis is established if at least 1 major and 1 minor or 3 minor criteria are fulfilled

Expression of CD2 and CD25 on Bone Marrow Mast Cells in a Patient with SM - Flow Cytometry



Detection of CD25 in Neoplastic Bone Marrow Mast Cells by Immunohistochemistry (IHC)



CD25-IHC :

- Easy Test
- Highly Specific (>95%) for neoplastic MC in SM
- MC in Myelomastocytic Leukemia & reactive MC Hyperplasia are CD25⁻
- Highly Sensitive and superior to CD2
- May be equally diagnostic compared to flow-cytometry analysis
- not yet accepted as a minor SM criterion

WHO Classification: Criteria for Systemic Mastocytosis (SM-Criteria)



Major Criteria


• Multifocal dense mast cell (MC) infiltrates (≥15 MC/infiltrate) in the bone marrow or in an other extracutaneous organ

Minor Criteria


- >25% spindle-shaped cells in MC-infiltates; or >25% of all MC are atypical MC (type I and/or type II) in bone marrow smears
- Expression of CD2 and/or CD25 on bone marrow MC
- Serum tryptase level >20 ng/ml (does not count in cases with an AHNMD)
- *c-kit* point mutation at codon 816 (mostly D816V) in bone marrow or in another extracutaneous organ

The diagnosis Systemic Mastocytosis is established if at least 1 major and 1 minor or 3 minor criteria are fulfilled


Serum Tryptase Levels in Hematologic Disorders



Correlation between Serum Tryptase Levels and Percentage of Mast Cell Infiltrates



Serum Tryptase Levels in various Groups of Patients with SM



WHO Classification: Criteria for Systemic Mastocytosis (SM-Criteria)

Major Criteria


• Multifocal dense mast cell (MC) infiltrates (≥15 MC/infiltrate) in the bone marrow or in an other extracutaneous organ

Minor Criteria

- >25% spindle-shaped cells in MC-infiltates; or >25% of all MC are atypical MC (type I and/or type II) in bone marrow smears
- Expression of CD2 and/or CD25 on bone marrow MC
- Serum tryptase level >20 ng/ml (does not count in cases with an AHNMD)
- *c-kit* point mutation at codon 816 (mostly D816V) in bone marrow or in another extracutaneous organ

The diagnosis Systemic Mastocytosis is established if at least 1 major and 1 minor or 3 minor criteria are fulfilled

c-kit Point Mutations in Mastocytosis



Proposed Standards (D816V)


- Bone marrow (bm) cells
- MNC or unfractionated bm cells analyzed
- In suspected smouldering SM or mast cell leukemia, peripheral blood (MNC) should also be analyzed
- **RT-PCR and RFLP**

(in D816V-negative patients \rightarrow sequencing of *c*-*kit*)

c-kit Point Mutations in Mastocytosis

Mutation	Reported in	Frequency in SM
c-kit D816V	<u>all</u> variants of SM some cases of CM	>80%
c-kit D816Y	ISM, SM-AHNMD, CM	? <5%
c-kit D816F	ISM, CM ?	<5%
c-kit D816H	SM-AHNMD	< 5%
c-kit D812G	SM/ASM	< 5%
c-kit D560G	SM/ISM	< 5%
c-kit F522C	SM/ISM	< 5%
c-kit E839K	CM	<5%
c-kit V531I	SM-AHNMD	< 5%
c-kit K509I	ISM/ASM	< 5%

THE NATURAL CLINICAL COURSE IN SYSTEMIC MASTOCYTOSIS



Doxycycline-Induced Expression of c-kit D816V in Ba/F3 Cells


Effects of c-kit D816V in Ba/F3 cells (Ton.Kit-D816V):


- Cluster Formation
- Differentiation

(early MC differentiation, histamine, ...)

- No Proliferation (!)


ASH 2004: Mayerhofer et al, Abstract no # 485






PATHOGENETIC CONCEPTS: ROLE OF OTHER DEFECTS

What factors and defects are responsible for the development of a high grade (mast cell-) disease in patients with c-kit-D816V⁺ SM



Stepwise Approach in Defining Subvariant of SM: Proposed Algorithm using WHO - Criteria



B-Findings (Borderline-Benign) and C-Findings (Consider Cytoreduction)

B-Findings:

- Infiltration grade (MC) in BM>30% and serum tryptase >200 ng/ml
- Dysmyelopoiesis: Hypercellular marrow with signs of myelodysplasia or myeloproliferation, but no criteria for MDS or MPD. Blood picture normal or slightly abnormal
- Organomegaly (without impairment of organ function): Hepatomegaly (without ascites), splenomegaly (palpable), lymphadenopathy (>2 cm in CT or US)

When 2 or 3 B-Findings but no C-Findings are recorded, the final diagnosis is Smouldering SM

C-Findings:

- One or more Cytopenias: ANC<1000/µl; Hb<10 g/dl; Plt<100000/µl
- **Hepatopathy:** Enlarged liver with ascites, elevated liver enzymes +/- portal hypertension
- **Organopathy of Spleen:** Splenomegaly with hypersplenism
- Malabsorbtion with hypalbuminemia and weight loss
- Large osteolysis and/or severe
 osteoporosis & pathologic fractures

Two Distinct Entities: Mast Cell Leukemia and Myelomastocytic Leukemia

Mast Cell Leukemia:

- SM Criteria Fulfilled
- c-kit Mutations (D816V)
- Karyotype often normal
- Atypical MC, MC-Blasts
- ≥ 20 % MC in BM smears
- Circulating Mast Cells
- No AHNMD no MDS/AML
- Usually, no CR after Induction Chemotherapy

Myelomastocytic Leukemia:


- Criteria of SM not met
- No c-kit Mutations
- Complex Karyotype
- Metachromatic Blasts
- ≥ 10 % MC in BM Smears or in Peripheral Blood
- AML or MDS-RAEB
- Usually, CR after
 Induction Chemotherapy

Mast Cell Leukemia (MCL)

Findings in MCL:

- SM Criteria Fulfilled
- Organopathy C-Finding(s)
- Atypical MC + MC Blasts
- ≥ 20 % MC in BM smears
 No AHNMD
- No Skin Lesions (!)
- Circulating MC:
 - $\geq 10\%$ = Typical MCL
 - <10% = Aleukemic MCL</p>

Bone marrow smear in MCL: Wright-Giemsa stain



Treatment of Patients with Mastocytosis

- A: Treatment of Mediator-Related Symptoms: Drugs Targeting – Mediator Production – Mediator Release – Mediator Effects
- B: Cytoreductive Therapy Drugs Targeting – Neoplastic Stem Cells – Progenitor Cells (IFNs) – Mast Cells – Specific Molecular Targets


Treatment of Mastocytosis: Mediator-Targeting Drugs

Pruritus, flushing	$H_1 + H_2$ antihistamines, ketotifen, topical glucocorticoids, avoid triggering factors	
Recurrent hypotension and tachycardia	$H_1 + H_2$ antihistamines, glucocorticoids, avoidance of triggering factors	
Recurrent shock	$H_1 + H_2$ antihistamines, glucocorticoids, epinephrin	
Co-existing allergy	$H_1 + H_2$ antihistamines, glucocorticoids, avoidance of triggering factors, hyposensitization	
Peptic ulcer disease	$H_1 + H_2$ antihistamines, proton pump inhibitors	
Diarrhea, abdominal pain, cramping, nausea	$H_1 + H_2$ antihistamines, oral cromolyn sodium, glucocorticoids, leukotriene antagonists	
Bone pain	Analgetics, radiation for severe localized bone pain	
Osteopenia, osteoporosis	Vitamin D, calcium, estrogen, testosteron, biphosphonates, low dose interferon-alpha (IFNα)	
Neurologic symptoms	$H_1 + H_2$ antihistamines, oral cromolyn sodium	


Therapy of Skin Lesions with Psoralen and UV-A Irradiation (PUVA)

Urticaria pigmentosa-like skin lesions in a patient with SM

prior to PUVA therapy



3 months after PUVA




Treatment of Mastocytosis: Cytoreductive Drugs

ISM	NO cytoreductive treatment (exception: severe osteopenia with risk of pathologic fracture, life threatening recurrent shock ?)	
SSM	Wait and watch in most cases. In select cases (with progression) consider IFN α , 2CdA, or targeted drugs	
SM-AHNMD	Treat AHNMD as if no SM is present, and SM as if no AHNMD had been diagnosed (e.g. ASM-AHNMD !)	
ASM with slow progression	IFN α+glucocorticoids, 2CdA , in case of hypersplenism due to splenomegaly (MC infiltrates) consider splenectomy (in the absence of D816V - consider Imatinib)	
ASM with rapid progression	Polychemotherapy ± 2CdA, IFNα, or glucocorticoids - in responding patients - consider stem cell transplantation (in the absence of D816V - consider Imatinib)	
MCL	Polychemotherapy or 2CdA (±IFNα or corticoids) - in responding patients - consider stem cell transplantation (in the absence of D816V, consider Imatinib)	

In all categories, mediator-targeting drugs are given as adjunct to cytoreductive therapy

Follow up of a Patient with ASM treated with Interferon-alpha-2b and Prednisone



Reported Effects of 2-Chloro-2'-Deoxyadenosine (2CdA) = Cladribine in Patients with Mastocytosis

Report	Patients	2CdA Schedule	Response
Tefferi et al. NEJM 2001;344:307	ASM, n=1	0.13 mg/kg/d 2 h-infusion, d1-5 4 cycles	MR
Escribano et al. Leuk Res 2002;26:1043	SM-NHL, n=1	0.15 mg/kg/d 3 h-infusion, d 1-5 5 cycles	not applicable (MC phenotype switch from CD2+ to CD2-)
Kluin-Nelemans et al. Blood 2003;102:4270	ISM/SSM, n=4, ASM, n=3, SM-AHNMD, n=3	0.1-0.13 mg/kg/d 2 h-infusion, d 1-5 up to 6 cycles	in ASM: MR (2/3), GPR (1/3)
Pardanani et al. Leuk Res 2004;28:127	ASM, n=4	0.14 mg/kg/d 2 h-infusion, d 1-5 3-6 cycles	MR (2/4), GPR (1/4) NR (1/4)
Lortholary et al. ASH 2004 # 661	ISM/SSM, n=6 ASM/MCL, n=23 SM-AHNMD, n=4	0.15 mg/kg/d 2 h-infusion, d 1-5 1-6 cycles	in all patients: MR in >50%

Major Responses (MR) in Patients with Aggressive Systemic Mastocytosis

MR rate


15-20 %

Therapy in ASM

Interferon-alpha 2b s.c. (9-42 million units per week) plus glucocorticoids

2-Chloro-2'-Deoxyadenosine (2CdA) = Cladribine i.v. (2-3 h) ~ 50 % 0.1-0.15 mg/kg/d, d 1-5, 1-6 cycles

Follow up of 2 Patients with SM during Therapy



Months

Targeted Drugs: Imatinib/STI571 and others

- Targets of Imatinib detectable in Mastocytosis:

- wt KIT (tyrosine kinase activation domain)
- mutated variants of KIT (D560G, F522C, ..)
 FIPL1/PDGFRA (SM-HES, SM-CEL, SM-eo)
 BCR/ABL (rare subvariant: SM-CML)
- D816V confers (relative) resistance against STI571
- New Kinase Inhibitors (PKC412, AMN107, BMS-354825,)
- Other Targets and Targeted Drugs (n > 100)

Targeted Drugs in Mastocytosis: Future Perspectives

TARGETED DRUG	DRUG TARGET(s)	SM VARIANT(s)
PKC412	wt KIT, KIT[mut]	- ASM, MCL, SM-AHNMD
AMN107	wt KIT, KIT[mut]	- ASM, MCL, SM-AHNMD
BMS354825	wt KIT, KIT[mut]	- ASM, MCL, SM-AHNMD
AP23464	KIT[mut], wt KIT	- ASM, MCL, SM-AHNMD
17AAG	Chaperone, KIT[mut]	- ASM, MCL, SM-AHNMD
Targeting Antibodies	CD25, CD33, CD44, CD52,	- ASM, MCL, SM-AHNMD
Antisense, siRNA	KIT, MITF, MCl-1,	- ASM, MCL, SM-AHNMD
VEGF-targeting Drugs	VEGF, Angiogenesis	- ASM, MCL, SM-AHNMD
FTIs (R115777), FTS	Farnesyltransferase	- ASM, MCL, SM-AHNMD
Rapamycin & Derivatives	mTOR, VEGF	- ASM, MCL, SM-AHNMD